CRISPR Therapeutics Unveils $280 Million Direct Offering
CRISPR Therapeutics (Nasdaq: CRSP), a leading biopharmaceutical company dedicated to pioneering transformative gene-based therapies for serious illnesses, has announced a strategic move in securing approximately $280 million through a registered…
European Commission Approves CASGEVY™ for SCD and TDT Treatment
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company dedicated to pioneering gene-based treatments for severe illnesses, disclosed today that the European Commission has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel…
New Findings from Phase 3 Trials of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa to be Revealed at EHSF 2024
Results from the latest analyses of bimekizumab phase 3 trials in patients with moderate to severe hidradenitis suppurativa (HS) will be presented at the 13th Conference of the European Hidradenitis…
Baxter Releases Financial Results for Q4 and FY 2023
Today, Baxter, a prominent player in the global medtech arena, disclosed its financial outcomes for the fourth quarter and the entirety of 2023, concluding on December 31st. Additionally, the company…
Novartis Secures Approval for Expanded Paediatric Chronic Heart Failure Indication for Entrust® Tablet, an Angiotensin Receptor Neprilysin Inhibitor (ARNI)
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that Novartis Pharma K.K. (Novartis Pharma) has received approval for an expanded treatment indication of pediatric chronic heart failure for Entresto® Tablets, an angiotensin…
Revamped Bon Curry NEO Line: Otsuka Foods Introduces Five Enhanced Products for a Flavorful Relaunch, Arriving in Stores on March 4, 2024
Today’s announcement unveils Otsuka Foods’ plans to introduce five revamped Bon Curry NEO products, each boasting a richer flavor profile, all under the renowned Bon Curry brand. Set for release…
Otsuka and Jolly Good Initiate Distribution of FACEDUO Content to Aid Families Supporting Individuals with Severe Social Withdrawal
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Jolly Good Inc. (Jolly Good) have commenced the delivery of innovative content aimed at supporting families of individuals in Japan grappling with severe social…
Biotech and Autoloops Forge Partnership for Advancing CAR-T Cell Therapy Pipeline and Scaling Late-Stage Initiatives
BioNTech SE (Nasdaq: BNTX, “BioNTech”), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, and Autolus Therapeutics plc (Nasdaq: AUTL, “Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T…
RSVVW Abstract Regarding mRNA-1345: Official Statement
At an upcoming presentation at the RSVVW’24 conference, Moderna will share follow-up data from its ongoing ConquerRSV Phase 3 study of its investigational RSV vaccine candidate, mRNA-1345. As previously published…
Takeda Plans Prompt Commencement of Global Phase 3 Trials for TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 by First Half of Fiscal Year 2024
Takeda (TSE:4502/NYSE:TAK) has unveiled positive topline findings from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial assessing TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients diagnosed with…
Positive Results for Mosunetuzumab in Japanese Phase I Study: Meeting Primary Endpoint for Relapsed and Refractory Follicular Lymphoma Expansion Cohort
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has revealed that the anti-CD20/CD3 bispecific antibody mosunetuzumab has successfully met the primary endpoint of achieving a complete response rate (CRR) in an expansion…
Crovalimab Becomes First Country Approved in China for Treating Paroxysmal Nocturnal Haemoglobinuria
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has announced today the approval of crovalimab (known as 派圣凯® in China), a humanized complement inhibitor C5 monoclonal antibody developed by Chugai, by the…